Weekly VELCADE in Combination with Rituximab Improves Progression-Free Survival and Response Rate in Patients with Relapsed or Refractory Follicular Lymphoma

-- Addition of VELCADE increased progression-free survival by 22 percent --

ORLANDO, Fla.--(BUSINESS WIRE)--Dec 7, 2010 - Millennium: The Takeda Oncology Company today reported the final results of a Phase III study comparing VELCADE® (bortezomib) for Injection and rituximab to rituximab alone for the treatment of patients with relapsed or refractory follicular lymphoma (FL) who were rituximab-naïve or -sensitive. These data were presented at the 52nd annual meeting of the American Society of Hematology (ASH), held December 4-7 in Orlando, Florida.

The randomized, international Phase III study enrolled 676 patients from 164 centers in 29 countries globally. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall response rate (ORR), complete response (CR) rate, time to next therapy (TTNT), and safety/tolerability. Efficacy endpoints were assessed by an independent review committee. The results, which were presented by Bertrand Coiffier, M.D., Hospices Civils de Lyon, Pierre-Benite, France, showed that patients receiving the VELCADE-rituximab combination had a 22 percent improvement in PFS after a median follow-up of 34 months (hazard ratio=0.822, p=0.039). Median PFS was 12.8 months in the VELCADE-rituximab arm, compared to 11 months with rituximab alone.

“The VELCADE-rituximab combination demonstrated an improvement in PFS, including in those patients with poor prognostic factors, and prolonged the time to next therapy. These are important clinical considerations in this advanced disease setting,” said Nancy Simonian, M.D., Chief Medical Officer, Millennium. “This combination with weekly VELCADE was generally well-tolerated, allowing most patients to complete the planned 20 weeks of therapy."

A Phase 3 Trial Comparing Bortezomib Plus Rituximab with Rituximab Alone In Patients with Relapsed, Rituximab-Naïve or –Sensitive, Follicular Lymphoma (Abstract #857)

This Phase III trial examined 676 patients with relapsed or refractory FL with a median age of 57. The results showed:

 

  • After a median follow-up of 33.9 months, the median PFS was 12.8 months in the VELCADE-rituximab arm, compared to 11 months in the rituximab arm (HR=0.822; P=0.039)
    • In patients with high tumor burden, median PFS was 11.3 months in the VELCADE-rituximab arm, compared with 8.4 months in the rituximab arm (HR=0.751, p=0.0186)
    • In patients with FLIPI scores of 3 or higher, median PFS was 11.4 months in the VELCADE-rituximab arm, compared with 7.9 months in the rituximab arm (HR=0.707, p=0.0133)
  • Median TTNT was 23 months in the VELCADE-rituximab arm, compared to 17.7 months in the rituximab arm (HR=0.802, p=0.027)
  • ORR was 63 percent in the VELCADE-rituximab arm, compared to 49 percent in the rituximab arm (p<0.001)
  • CR rate was 25 percent in the VELCADE-rituximab arm, compared to 18 percent in the rituximab arm (p=0.035)
  • Median number of cycles was 5 in both arms
  • The overall rate of Grade 3 and higher adverse events was 46 percent in the VELCADE-rituximab arm and 21 percent in the rituximab arm
  • In the VELCADE-rituximab arm, 16 percent of patients experienced peripheral neuropathy of any Grade vs. one percent in the rituximab arm; three percent of patients experienced peripheral neuropathy of Grade 3 or higher, while there were no reports in the rituximab arm

In this trial, patients with grade 1-2 measurable relapsed or refractory FL who had progressed following prior therapy (time to progression [TTP] ‰¥6 months if prior rituximab-containing therapy), ECOG performance status less than 2, and no peripheral neuropathy of grade ‰¥2 were randomized (1:1) to receive 5-week cycles of weekly VELCADE (Vc)-rituximab (R) (Vc 1.6 mg/m2, d 1, 8, 15, 22, cycles 1–5, plus R 375 mg/m2, d 1, 8, 15, 22 in cycle 1 and d 1 only in cycles 2–5) or R alone. In both groups, treatment was administered for five cycles or until progression or unacceptable treatment-related toxicity. Randomization was stratified by FLIPI score (0–1 vs. 2 vs. ‰¥3), prior R therapy (yes vs. no), time since last dose of anti-FL therapy (‰¤1 vs. >1 year), and region (US vs. EU vs. rest of world).

About Millennium

Millennium: The Takeda Oncology Company, a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE, a first-in-class proteasome inhibitor, and has a robust clinical development pipeline of product candidates. Millennium Pharmaceuticals, Inc. was acquired by Takeda Pharmaceutical Company Ltd. in May, 2008. The Company's research, development and commercialization activities are focused in oncology. Additional information about Millennium is available through its website, www.millennium.com.

About VELCADE

VELCADE is co-developed by Millennium and Ortho Biotech Oncology Research & Development, a unit of Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Millennium is responsible for commercialization of VELCADE in the U.S., Janssen-Cilag is responsible for commercialization in Europe and the rest of the world. Takeda Pharmaceutical Company Limited and Janssen Pharmaceutical K.K. entered into a co-promote agreement in May 2010 for VELCADE in Japan. VELCADE is approved in more than 90 countries and has been used to treat more than 160,000 patients worldwide.


Indications and Important Safety Information

What is VELCADE® (bortezomib) Used For?
VELCADE is approved for the treatment of patients with multiple myeloma (a cancer of the plasma cells). VELCADE is also approved for the treatment of patients with mantle cell lymphoma (a cancer of lymph nodes) who have already received other treatments.

How is VELCADE administered?
VELCADE is prescribed by a physician experienced in the use of medications to treat cancer. It is administered as an injection into your vein (IV) by a health care professional.

Who Should Not Receive VELCADE?
Before you receive treatment with VELCADE, tell your doctor about all of your medical conditions. You should not receive VELCADE if you are:

 

  • allergic to bortezomib, boron or mannitol
  • pregnant or plan to become pregnant
  • breastfeeding. Discuss with your doctor when it is safe to restart breastfeeding after finishing your treatment.

The effects of VELCADE in children have not been evaluated.

What are the Possible Side Effects of VELCADE?
VELCADE can cause serious side effects including:

 

  • Neutropenia (low levels of neutrophils, a type of white blood cell) and Thrombocytopenia (low levels of platelets). VELCADE can cause low levels of white blood cells (infection fighting cells) and/or platelets (clot-forming cells). You will have regular blood tests to check your cell counts during your treatment with VELCADE. If the number of these cells is very low, your doctor may change the dose and/or schedule of VELCADE. If your white blood cells become low, you can be at higher risk for infections. Tell your doctor if you develop a fever or believe you have an infection. If platelets become very low, there is an increased risk of bleeding. Your doctor may recommend a platelet transfusion. There have been cases of bleeding in the stomach, bowels and brain during treatment with VELCADE.
  • Gastrointestinal Problems. VELCADE treatment can cause nausea, vomiting, diarrhea, and constipation. If your symptoms are severe, your doctor may recommend IV fluids and/or medications.
  • Peripheral neuropathy. VELCADE can cause damage to the nerves, a condition called peripheral neuropathy. You may feel muscle weakness, tingling, burning, pain, and loss of feeling in your hands and feet, any of which can be severe. Tell your doctor if you notice any of these symptoms. Your doctor may change the dose and/or schedule of VELCADE or stop it altogether.
  • Low blood pressure. VELCADE can cause a drop in blood pressure. Tell your doctor if you have low blood pressure, feel dizzy or feel as though you might faint. If you are taking drugs that lower blood pressure, your medications might need to be adjusted. If you are not drinking enough liquids, your doctor may need to administer IV fluids.
  • Heart problems. VELCADE treatment can cause or worsen heart rhythm problems and heart failure. Your doctor may closely monitor you if you have, or are at risk for, heart disease. Tell your doctor if you experience chest pressure or pain, palpitations, swelling of your ankles or feet, or shortness of breath.
  • Lung Disorders. There have been reports of lung disorders in patients receiving VELCADE. Some of these events have been fatal. Tell your doctor if you experience any cough, shortness of breath, wheezing or difficulty breathing.
  • Liver disease. If you have liver problems, it can be harder for your body to get rid of VELCADE. VELCADE has caused sudden liver failure in patients who were taking many medications or had other serious medical conditions. Symptoms of liver problems include a yellow discoloration of the eyes and skin (jaundice) and changes in liver enzymes measured in blood tests. Your doctor will closely monitor you if you have liver disease. In patients with moderate or severe liver disease, VELCADE should be started at a lower dose. Additional dose adjustments may be made based on your tolerance of the drug.
  • Tumor Lysis Syndrome (TLS). TLS can occur with cancer treatments and your doctor will be monitoring blood and urine for any signs of this syndrome. If you develop TLS, your doctor will take appropriate steps to treat it.
  • Reversible Posterior Leukoencephalopathy Syndrome (RPLS). There have been reports of a rare, reversible condition involving the brain called RPLS in patients treated with VELCADE. Patients with RPLS can have seizures, high blood pressure, headaches, tiredness, confusion, blindness or other vision problems. VELCADE treatment should be stopped in cases of RPLS.

The most common side effects seen in patients receiving VELCADE include: thrombocytopenia, neutropenia, nausea, peripheral neuropathy, neuralgia (nerve pain), pyrexia (high temperature), diarrhea, anemia, leukopenia (low levels of white blood cells), decreased appetite, fatigue, constipation, vomiting, dehydration, dyspnea (difficulty breathing), cough, asthenia (low energy), insomnia (trouble sleeping), peripheral edema (swelling of the limbs), and headache.

What other information should you discuss with your doctor?

You should also tell your doctor if you:

 

  • have kidney disease. If you are on dialysis, your doctor will administer VELCADE after the dialysis procedure.
  • are taking medication for diabetes. VELCADE can affect your blood glucose levels. Your doctor may require close monitoring of your blood glucose levels and change the dose of your diabetes medicine while you are being treated with VELCADE.
  • have liver disease.
  • are using medicines like ketoconazole (an anti-fungal) and ritonavir (an anti-viral), which will require close monitoring during treatment with VELCADE.
  • are using any other medications (including over the counter drugs), herbal or dietary supplements, or holistic treatments.
  • develop a rash of any type while receiving VELCADE.

The side effects of VELCADE may impair your ability to drive or operate machinery.

These are not all of the possible side effects with VELCADE. It is important to always contact your doctor if you experience any side effects while on VELCADE. If you have any questions about VELCADE, contact your doctor. Additional information and full prescribing information is available at www.VELCADE.com.

Please see the full prescribing information for VELCADE including warnings and precautions.

For more information about VELCADE clinical trials, patients and physicians can contact the Millennium Medical Product Information Department at 1-866-VELCADE (1-866-835-2233).

Editors' Note: This press release is also available under the Media section of the Company's website at: www.millennium.com/media

 

Contact: Millennium
Manisha Pai, 617-551-7877
Manisha.Pai@mpi.com
or
Lauren Musto, 617-551-7848
Lauren.Musto@mpi.com

 

 

Posted: December 2010

View comments

Hide
(web5)